138 related articles for article (PubMed ID: 34036396)
1. Interaction between CD9 and PI3K‑p85 activates the PI3K/AKT signaling pathway in B‑lineage acute lymphoblastic leukemia.
Shi YF; Huang ZY; Huang YS; Dong RJ; Xing CY; Yu K; Leung KT; Feng JH
Oncol Rep; 2021 Jul; 46(1):. PubMed ID: 34036396
[TBL] [Abstract][Full Text] [Related]
2. CD9 knockdown suppresses cell proliferation, adhesion, migration and invasion, while promoting apoptosis and the efficacy of chemotherapeutic drugs and imatinib in Ph+ ALL SUP‑B15 cells.
Xing C; Xu W; Shi Y; Zhou B; Wu D; Liang B; Zhou Y; Gao S; Feng J
Mol Med Rep; 2020 Oct; 22(4):2791-2800. PubMed ID: 32945456
[TBL] [Abstract][Full Text] [Related]
3. CD9 regulates keratinocyte differentiation and motility by recruiting E-cadherin to the plasma membrane and activating the PI3K/Akt pathway.
Jiang X; Teng M; Ji R; Zhang D; Zhang Z; Lv Y; Zhang Q; Zhang J; Huang Y
Biochim Biophys Acta Mol Cell Res; 2020 Feb; 1867(2):118574. PubMed ID: 31682865
[TBL] [Abstract][Full Text] [Related]
4. Potential efficacy and prognosis of silencing the CRLF2‑mediated AKT/mTOR pathway in pediatric acute B‑cell lymphoblastic leukemia.
Jiang M; Zou X; Lu L
Oncol Rep; 2019 Feb; 41(2):885-894. PubMed ID: 30535452
[TBL] [Abstract][Full Text] [Related]
5. Down-regulation of miRNA-196b expression inhibits the proliferation, migration and invasiveness of HepG2 cells while promoting their apoptosis via the PI3K/Akt signaling pathway.
Xu F; Zhu F; Wang W; Gao W; Chen X; Yu C
Cell Mol Biol (Noisy-le-grand); 2020 Jun; 66(3):159-164. PubMed ID: 32538764
[TBL] [Abstract][Full Text] [Related]
6. CD9, a key actor in the dissemination of lymphoblastic leukemia, modulating CXCR4-mediated migration via RAC1 signaling.
Arnaud MP; Vallée A; Robert G; Bonneau J; Leroy C; Varin-Blank N; Rio AG; Troadec MB; Galibert MD; Gandemer V
Blood; 2015 Oct; 126(15):1802-12. PubMed ID: 26320102
[TBL] [Abstract][Full Text] [Related]
7. NLRC5 promotes cell migration and invasion by activating the PI3K/AKT signaling pathway in endometrial cancer.
Fan Y; Dong Z; Shi Y; Sun S; Wei B; Zhan L
J Int Med Res; 2020 May; 48(5):300060520925352. PubMed ID: 32431202
[TBL] [Abstract][Full Text] [Related]
8. Activation of PI3K-Akt signaling pathway promotes prostate cancer cell invasion.
Shukla S; Maclennan GT; Hartman DJ; Fu P; Resnick MI; Gupta S
Int J Cancer; 2007 Oct; 121(7):1424-32. PubMed ID: 17551921
[TBL] [Abstract][Full Text] [Related]
9. PI3K/AKT phosphorylation activates ERRα by upregulating PGC‑1α and PGC‑1β in gallbladder cancer.
Wang L; Yang M; Jin H
Mol Med Rep; 2021 Aug; 24(2):. PubMed ID: 34184087
[TBL] [Abstract][Full Text] [Related]
10. Down-regulation of Rictor enhances cell sensitivity to PI3K inhibitor LY294002 by blocking mTORC2-medicated phosphorylation of Akt/PRAS40 in esophageal squamous cell carcinoma.
Hou G; Zhao Q; Zhang M; Fan T; Liu M; Shi X; Ren Y; Wang Y; Zhou J; Lu Z
Biomed Pharmacother; 2018 Oct; 106():1348-1356. PubMed ID: 30119206
[TBL] [Abstract][Full Text] [Related]
11. Elucidating the role of the FoxO3a transcription factor in the IGF-1-induced migration and invasion of uveal melanoma cancer cells.
Yan F; Liao R; Farhan M; Wang T; Chen J; Wang Z; Little PJ; Zheng W
Biomed Pharmacother; 2016 Dec; 84():1538-1550. PubMed ID: 27881235
[TBL] [Abstract][Full Text] [Related]
12. Cisplatin and PI3kinase inhibition decrease invasion and migration of human ovarian carcinoma cells and regulate matrix-metalloproteinase expression.
Karam AK; Santiskulvong C; Fekete M; Zabih S; Eng C; Dorigo O
Cytoskeleton (Hoboken); 2010 Aug; 67(8):535-44. PubMed ID: 20607860
[TBL] [Abstract][Full Text] [Related]
13. Phosphatidylinositol 3-kinase-Akt signaling in pulmonary carcinoid cells.
Pitt SC; Chen H; Kunnimalaiyaan M
J Am Coll Surg; 2009 Jul; 209(1):82-8. PubMed ID: 19651067
[TBL] [Abstract][Full Text] [Related]
14. Inhibition of EGFR/PI3K/AKT cell survival pathway promotes TSA's effect on cell death and migration in human ovarian cancer cells.
Zhou C; Qiu L; Sun Y; Healey S; Wanebo H; Kouttab N; Di W; Yan B; Wan Y
Int J Oncol; 2006 Jul; 29(1):269-78. PubMed ID: 16773209
[TBL] [Abstract][Full Text] [Related]
15. Adult B-cell acute lymphoblastic leukemia cells display decreased PTEN activity and constitutive hyperactivation of PI3K/Akt pathway despite high PTEN protein levels.
Gomes AM; Soares MV; Ribeiro P; Caldas J; Póvoa V; Martins LR; Melão A; Serra-Caetano A; de Sousa AB; Lacerda JF; Barata JT
Haematologica; 2014 Jun; 99(6):1062-8. PubMed ID: 24561792
[TBL] [Abstract][Full Text] [Related]
16. LY‑294002 enhances the chemosensitivity of liver cancer to oxaliplatin by blocking the PI3K/AKT/HIF‑1α pathway.
Xu R; Zhang Y; Li A; Ma Y; Cai W; Song L; Xie Y; Zhou S; Cao W; Tang X
Mol Med Rep; 2021 Jul; 24(1):. PubMed ID: 33982772
[TBL] [Abstract][Full Text] [Related]
17. Anti-myeloma activity of Akt inhibition is linked to the activation status of PI3K/Akt and MEK/ERK pathway.
Ramakrishnan V; Kimlinger T; Haug J; Painuly U; Wellik L; Halling T; Rajkumar SV; Kumar S
PLoS One; 2012; 7(11):e50005. PubMed ID: 23185517
[TBL] [Abstract][Full Text] [Related]
18. RUNX2 Plays An Oncogenic Role in Esophageal Carcinoma by Activating the PI3K/AKT and ERK Signaling Pathways.
Lu H; Jiang T; Ren K; Li ZL; Ren J; Wu G; Han X
Cell Physiol Biochem; 2018; 49(1):217-225. PubMed ID: 30138923
[TBL] [Abstract][Full Text] [Related]
19. Absence of CD9 enhances adhesion-dependent morphologic differentiation, survival, and matrix metalloproteinase-2 production in small cell lung cancer cells.
Saito Y; Tachibana I; Takeda Y; Yamane H; He P; Suzuki M; Minami S; Kijima T; Yoshida M; Kumagai T; Osaki T; Kawase I
Cancer Res; 2006 Oct; 66(19):9557-65. PubMed ID: 17018612
[TBL] [Abstract][Full Text] [Related]
20. RNA interference of PARG could inhibit the metastatic potency of colon carcinoma cells via PI3-kinase/Akt pathway.
Li Q; Li M; Wang YL; Fauzee NJ; Yang Y; Pan J; Yang L; Lazar A
Cell Physiol Biochem; 2012; 29(3-4):361-72. PubMed ID: 22508044
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
